Every 8-K that Personalis (PSNL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PSNL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PSNL filings page.
Personalis, Inc. (PSNL) reported receiving a new task order under its contract with the U.S. Department of Veterans Affairs for the Million Veteran Program. The task order becomes effective on September 30, 2026 and has a value of up to $18.3 million, conditioned on receipt of samples and performance of services.
With this award, the cumulative value of task orders Personalis has received under its contracts with the VA’s Million Veteran Program has increased to approximately $243.3 million. Personalis also highlighted that actual revenue from this work will depend on sample volume, execution under the task order, and ongoing demand from the program.
Personalis, Inc. reported second quarter 2026 revenue of $22.4 million, up from $17.2 million a year earlier, a 30% increase driven mainly by pharma testing services and rapid growth in clinical testing. Clinical diagnostic revenue rose to $2.6 million from $0.5 million as clinical test volume climbed to 10,384 tests, a 199% year-over-year and 33% sequential increase, while pharma testing services generated $16.8 million versus $11.1 million and population sequencing revenue was $3.0 million versus $3.3 million.
The company reported a net loss of $31.7 million, or $0.30 per share, compared with a net loss of $20.1 million, or $0.23 per share, in the prior-year quarter. Cash, cash equivalents and short-term investments totaled approximately $212.7 million as of June 30, 2026.
Strategically, Personalis secured new Medicare coverage for its NeXT Personal assay in immunotherapy monitoring and neoadjuvant breast cancer settings, highlighted data showing 100% relapse detection in the VICTORI colorectal study, and emphasized the importance of sub-10 ppm ctDNA sensitivity in lung cancer. Following a July 20, 2026 merger agreement with Tempus AI, Inc., Personalis will no longer provide financial guidance or hold quarterly earnings calls.
Personalis, Inc. agreed to be acquired by Tempus AI, Inc. through a two-step merger in which a Tempus subsidiary will merge with Personalis, and the combined entity will then merge into another Tempus subsidiary, leaving Personalis as part of a wholly owned Tempus unit. Personalis stockholders’ shares will be converted into the right to receive an equity-based Merger Consideration in Tempus Class A common stock, determined by an exchange ratio tied to a volume‑weighted average Tempus share price before closing, with the parties intending the transaction to qualify as a tax reorganization under Section 368(a).
Closing is subject to multiple conditions, including approval by a majority of Personalis common shares, Nasdaq listing of the Tempus stock to be issued, effectiveness of a Form S‑4 registration statement, HSR and other antitrust clearances, tax opinions, and the absence of specified material adverse effects. Deal protections include a no‑shop with customary fiduciary out and matching rights, a $76.8 million termination fee payable by Personalis in certain break‑fee scenarios and a matching $76.8 million reverse termination fee payable by Tempus if closing fails under defined regulatory or timing conditions, with an Outside Date of April 20, 2027 and potential extensions. Personalis may terminate if the Tempus share price used in the exchange formula falls below a $46.00 lower floor price, and a separate Voting Agreement commits Merck Sharp & Dohme, holding about 13% of Personalis voting power, to support the merger.
Personalis, Inc. agreed to be acquired by Tempus AI, Inc. under a definitive merger agreement announced on July 20, 2026. Personalis shareholders are expected to receive $16.25 per share, implying an enterprise value of $1.5 billion net of Tempus’s existing ownership, in a transaction structured as stock with up to half of the consideration potentially payable in cash at Tempus’s discretion. The deal represents a 6% premium to the prior Friday close and a 28% premium to the unaffected 30‑day volume-weighted average price.
The combination is intended to integrate Personalis’ tumor-informed minimal residual disease technology with Tempus’s AI-enabled precision oncology and multimodal data platform, targeting what the companies describe as a $20 billion MRD market opportunity. Closing is expected in late 2026 or early 2027, subject to Personalis shareholder approval, regulatory approvals and other customary conditions, including a Tempus share-price condition. Personalis also reported preliminary Q2 revenue of $22.4 million and delivery of 10,384 clinical tests, a 33% quarter‑over‑quarter increase in test volumes.
Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for its ultrasensitive NeXT Personal test. As of May 19, 2026, coverage now includes monitoring response to neoadjuvant therapy in patients with Stage II–III triple‑negative or HER2‑positive breast cancer.
Personalis, Inc. reported the results of its 2026 annual meeting of stockholders. Shareholders representing 91,869,300 shares, or 87.76% of the 104,677,900 shares outstanding as of March 17, 2026, were present, establishing a quorum to conduct business.
Two Class I directors, Olivia K. Bloom and Woodrow A. Myers, Jr., M.D., were elected to serve until the 2029 annual meeting, with 75,695,538 and 68,240,509 votes cast in their favor, respectively. Stockholders also ratified BDO USA, P.C. as independent registered public accounting firm for the year ending December 31, 2026, with 91,586,300 votes for. In an advisory vote, stockholders approved the compensation of the company’s named executive officers, with 75,549,455 votes for and relatively few votes against or abstentions.
Personalis, Inc. reported that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has expanded Medicare coverage for its ultrasensitive NeXT Personal® test. The expansion now includes use of the test for immunotherapy monitoring in patients with late-stage solid tumors.
This change means NeXT Personal can be covered by Medicare when used to track how late-stage solid tumor patients respond to immunotherapy, potentially broadening clinical use within the Medicare population.
Personalis, Inc. reported first quarter 2026 revenue of $15.5 million, down from $20.6 million a year earlier as non-core revenue declined while the company shifted focus to its minimal residual disease (MRD) offering. The net loss widened to $30.0 million, compared with $15.8 million in the prior-year quarter, as operating expenses increased.
Clinical test revenue rose to $1.4 million from $0.3 million, with clinical test volume surging 258% year-over-year to 7,815 tests, helped by growth in the NeXT Personal MRD test. Personalis secured Medicare coverage for lung cancer surveillance, adding to existing breast cancer coverage, and ended the quarter with about $233.2 million in cash, cash equivalents and short-term investments.
The company reaffirmed its full-year 2026 outlook, including total revenue of $78.0–$80.0 million, clinical test volume of 43,000–45,000 tests, clinical revenue of $10.0–$11.0 million, gross margin of 15%–20%, a net loss of about $105.0 million, and projected cash usage of about $100.0 million.
Personalis, Inc. appointed Richard Chen as President, adding to his roles as Executive Vice President, R&D, and Chief Medical Officer. Christopher Hall previously served as President and remains Chief Executive Officer.
Chen’s annual base salary will increase to $570,000 effective April 1, 2026, with a performance bonus target set at 70% of his then-current base salary. On March 15, 2026, he will receive an option to purchase 37,500 shares of common stock at the March 13, 2026 closing price, vesting in equal monthly installments over 36 months, and a restricted stock unit award covering 6,250 shares, vesting over time starting six months after the grant date, in each case subject to continued service under the company’s 2019 Equity Incentive Plan.
Personalis, Inc. reported fourth quarter and full year 2025 results and issued 2026 guidance, highlighting rapid growth in its clinical testing business alongside continued losses. Full year 2025 revenue was $69.6 million, down from $84.6 million, with a net loss of $81.3 million. However, clinical test volume surged nearly 400% to 16,233 tests, and Q4 clinical test revenue rose to $0.9 million from $0.2 million. The company ended 2025 with about $240 million in cash, cash equivalents and short-term investments, including $109 million of ATM proceeds. For 2026, Personalis guides to revenue of $78–$80 million, clinical revenue of $10–$11 million on 43,000–45,000 tests, and expects a net loss of about $105 million and cash usage of about $100 million as it invests behind 5x projected clinical revenue growth.
Personalis, Inc. reported that it has released certain preliminary financial and operational results for the quarter and fiscal year ended December 31, 2025. These results were announced through a press release dated January 8, 2026.
The company furnished the full text of this press release as Exhibit 99.1 to the current report, incorporating it by reference for informational purposes. The information in this report, including Exhibit 99.1, is provided under special Exchange Act provisions so it is not treated as formally filed or automatically incorporated into other securities law filings unless specifically referenced.
Personalis, Inc. announced that the Centers for Medicare & Medicaid Services Molecular Diagnostics Program has revised its Medicare reimbursement rates for the company’s ultrasensitive NeXT Personal® test used to monitor cancer recurrence in stage II and III breast cancer patients. Effective December 1, 2025, the NeXT Personal Dx Breast MRD Recurrence Monitoring Test will be reimbursed at $4,266 and the NeXT Personal Single Plasma Test at $1,164. Medicare will cover the Dx Breast MRD Recurrence Monitoring Test once per cancer diagnosis, while the Single Plasma Test is covered for up to six years after treatment, shaping how often these tests can be used for long-term patient surveillance.
Personalis (PSNL) announced that its ultrasensitive NeXT Personal tests received Medicare coverage for post‑treatment surveillance of cancer recurrence in stage II and III breast cancer. The determination from the Centers for Medicare & Medicaid Services Molecular Diagnostics Program is effective retroactively as of October 7, 2025.
The NeXT Personal Dx Breast MRD Recurrence Monitoring Test is covered at a reimbursement rate of $3,878 and is available once per cancer diagnosis. The NeXT Personal Single Plasma Test is covered at $1,158 and is available for up to six years post‑treatment. This expands access and establishes defined payment levels for these assays among eligible Medicare patients.
Personalis, Inc. (PSNL) furnished an 8-K under Item 2.02 announcing it issued a press release with financial results for the quarter ended September 30, 2025.
The full text of the release is provided as Exhibit 99.1 and is incorporated herein by reference. The information, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other Securities Act or Exchange Act filings except as expressly set forth by specific reference.